4.3 Article

A six gene expression signature defines aggressive subtypes and predicts outcome in childhood and adult acute lymphoblastic leukemia

Journal

ONCOTARGET
Volume 6, Issue 18, Pages 16527-16542

Publisher

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.4113

Keywords

cancer; personalized medicine; risk stratification; minimum residual disease; cancer stem cells

Funding

  1. INCa
  2. ANR EpiSperm programs
  3. ANR grant
  4. Innovation Program of Shanghai Municipal Education Commission [13zz088]
  5. Ministry of Health Grant [201202003]
  6. NIH [R01 CA140729]
  7. INCa epigenetique et cancer programme
  8. ARC
  9. Fondation de France and Ligue Contre le Cancer (Comite Isere et Haute-Savoie)
  10. Laboratoire d'excellence Toucan (Toulouse Cancer)

Ask authors/readers for more resources

Abnormal gene expression in cancer represents an under-explored source of cancer markers and therapeutic targets. In order to identify gene expression signatures associated with survival in acute lymphoblastic leukemia (ALL), a strategy was designed to search for aberrant gene activity, which consists of applying several filters to transcriptomic datasets from two pediatric ALL studies. Six genes whose expression in leukemic blasts was associated with prognosis were identified: three genes predicting poor prognosis (AK022211, FASTKD1 and STARD4) and three genes associated with a favorable outcome (CAMSAP1, PCGF6 and SH3RF3). Combining the expression of these 6 genes could successfully predict prognosis not only in the two discovery pediatric ALL studies, but also in two independent validation cohorts of adult patients, one from a publicly available study and one consisting of 62 newly recruited Chinese patients. Moreover, our data demonstrate that our six gene based test is particularly efficient in stratifying MLL or BCR. ABL negative patients. Finally, common biological traits characterizing aggressive forms of ALL in both children and adults were found, including features of dormant hematopoietic stem cells, suggesting new therapeutic strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available